Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study.
Aged
Antineoplastic Agents, Immunological
B7-H1 Antigen
/ blood
Biomarkers, Tumor
Carcinoma, Non-Small-Cell Lung
/ diagnosis
Cell Line, Tumor
Circulating MicroRNA
Female
Gene Expression Profiling
Humans
Immunohistochemistry
Immunotherapy
Kaplan-Meier Estimate
Lung Neoplasms
/ diagnosis
Male
Middle Aged
Neoplasm Staging
Prognosis
Treatment Outcome
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 04 2019
01 04 2019
Historique:
received:
22
06
2018
revised:
18
10
2018
accepted:
03
01
2019
pubmed:
9
1
2019
medline:
12
5
2020
entrez:
9
1
2019
Statut:
ppublish
Résumé
Immune-checkpoint inhibitors (ICI) have improved the survival of patients with non-small cell lung cancer (NSCLC). However, only a subset of patients benefit from ICIs, and the role of PD-L1 as predictive biomarker is still debated. A plasma immune-related miRNA-signature classifier (MSC) was established in lung cancer screening settings to identify the lethal form of the disease in early stages. In this exploratory study, we tested the efficacy of the MSC as prognostic marker in patients with advanced NSCLC treated with ICIs. The MSC risk level was prospectively assessed in a consecutive series of 140 patients with NSCLC before starting treatment with ICIs. Overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) in strata of PD-L1 and MSC alone or combined were considered as endpoints. Multiple plasma samples to monitor MSC risk level during treatment were also profiled. Adequate tissue and plasma samples were available from 111 (79%) and 104 (75%) patients with NSCLC, respectively. MSC risk level was associated with ORR ( The plasma MSC test could supplement PD-L1 tumor expression to identify a subgroup of patients with advanced lung cancer with worse ORR, PFS, and OS in immunotherapy regimens.
Identifiants
pubmed: 30617131
pii: 1078-0432.CCR-18-1981
doi: 10.1158/1078-0432.CCR-18-1981
pmc: PMC6445748
mid: NIHMS1518455
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
B7-H1 Antigen
0
Biomarkers, Tumor
0
CD274 protein, human
0
Circulating MicroRNA
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2166-2173Subventions
Organisme : NCI NIH HHS
ID : U01 CA166905
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA214195
Pays : United States
Informations de copyright
©2019 American Association for Cancer Research.
Références
Mol Oncol. 2017 Dec;11(12):1673-1686
pubmed: 29024380
J Thorac Oncol. 2017 Jun;12(6):922-931
pubmed: 28302568
Ann Oncol. 2017 Aug 1;28(8):1996-2001
pubmed: 28459943
Cancer. 2018 Jan 15;124(2):248-261
pubmed: 29211297
Clin Cancer Res. 2017 Apr 15;23(8):1920-1928
pubmed: 27827313
J Immunol. 2014 Feb 1;192(3):1034-43
pubmed: 24391219
J Thorac Oncol. 2018 Sep;13(9):1302-1311
pubmed: 29800747
J Clin Oncol. 2018 Mar 1;36(7):633-641
pubmed: 29337640
Molecules. 2014 Mar 10;19(3):3038-54
pubmed: 24619302
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
Ann Oncol. 2018 Apr 1;29(4):959-965
pubmed: 29408986
Lancet. 1998 Apr 18;351(9110):1179
pubmed: 9643696
Acta Oncol. 2018 Sep;57(9):1225-1231
pubmed: 29683761
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
Genes Immun. 2014 Mar;15(2):115-25
pubmed: 24401767
Oncogene. 2014 Sep 18;33(38):4623-31
pubmed: 24141774
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Clin Cancer Res. 2019 Feb 1;25(3):989-999
pubmed: 30206165
Nat Cell Biol. 2016 Jul;18(7):790-802
pubmed: 27295554
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Oncotarget. 2015 Oct 20;6(32):32868-77
pubmed: 26451608
J Thorac Oncol. 2019 Jan;14(1):25-36
pubmed: 30253973
Oncoimmunology. 2016 Nov 8;6(1):e1253655
pubmed: 28197369
Clin Cancer Res. 2018 Apr 15;24(8):1872-1880
pubmed: 29330207
Clin Radiol. 2017 May;72(5):389-400
pubmed: 28168954
J Vis Exp. 2017 Oct 26;(128):
pubmed: 29155727
Nat Cell Biol. 2011 Dec 18;14(2):159-67
pubmed: 22179046
Nat Med. 2018 Sep;24(9):1441-1448
pubmed: 30082870
Int J Cancer. 2019 Jun 1;144(11):2746-2761
pubmed: 30426475
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
Science. 2016 Mar 25;351(6280):1463-9
pubmed: 26940869
Biol Cell. 2015 Mar;107(3):61-77
pubmed: 25564937
J Clin Oncol. 2014 Mar 10;32(8):768-73
pubmed: 24419137
Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3713-8
pubmed: 21300873
J Thorac Oncol. 2018 Aug;13(8):1156-1170
pubmed: 29777823
Immunotherapy. 2018 Feb;10(2):93-105
pubmed: 29145737
Oncogene. 2015 Nov 26;34(48):5857-68
pubmed: 25867073
Eur J Cancer. 2017 Nov;86:349-357
pubmed: 29078173
Clin Cancer Res. 2018 May 15;24(10):2268-2275
pubmed: 29326281